DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Nolan B, Mahlangu J, Young G. et al.
ASPIRE final results confirm established safety and sustained efficacy for up to 4 years of treatment with rFVIIIFc in previously treated subjects with severe hemophilia A.
Blood 2018;
132 (Supplement 1): 1192
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.